Stockreport

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Protei...

Savara, Inc.  (SVRA) 
Last savara, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: savarapharma.com/investors/events-presentations
PDF -- Priority Review Was Requested, Commercial Launch Preparations Underway ---- MOLBREEVI Has the Potential to Be the First and Only Approved Therapy for aPAP in the U.S. [Read more]